作者: TCMFINDER 2021-09-22 13:42:00
Abstract for Reference 4: Treatment of androgeneticalopecia in men4TIEfficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review.AUMella JM, Perret MC, Manzotti M, Catalano HN, Guyatt GSOArch Dermatol. 2010;146(10):1141.CONTEXT: Androgenetic alopecia is the most common form of alopecia in men.OBJECTIVE: To determine the efficacy and safety offinasteride therapy for patients with androgeneticalopecia.DATA SOURCES: MEDLINE, EMBASE, CINAHL, Cochrane Registers, and LILACS were searched for randomized controlled trials reported in any language that evaluated the efficacy and safety of finasteride therapyin comparison to treatment with placebo in adultswith androgenetic alopecia.STUDY SELECTION AND DATA EXTRACTION: Two reviewersindependently evaluated eligibility and collectedthe data, including assessment of methodological quality (Jadad score). Outcome measures included patient self-assessment, hair count, investigator clinical assessment, global photographic assessment, and adverse effects at short term ( 12 months) and lDATA SYNTHESIS: Twelve studies fulfilled the eligibility criteria (3927 male patients), 10 of which demonstrated a Jadad score of 3 or more. The proportion of patients reporting an improvement in scalp hair was greater with finasteride therapy than with placebo treatment in the short term (relative risk [RR], 1.81 [95% confidence interval (CI), 1.42-2.32]; I눬 64%) and in the long term (RR, 1.71 [95% CI,CONCLUSION: Moderate-quality evidence suggests thatdaily use of oral finasteride increases hair countandimproves patient and investigator assessment ofhair appearance, while increasing the risk of sexual dysfunction.ADDepartment of Internal Medicine, Hospital Alem嫕, APMID20956649